PMID- 31087709
OWN - NLM
STAT- MEDLINE
DCOM- 20200817
LR  - 20200817
IS  - 1097-4644 (Electronic)
IS  - 0730-2312 (Linking)
VI  - 120
IP  - 9
DP  - 2019 Sep
TI  - Oxymatrine ameliorates insulin resistance in rats with type 2 diabetes by 
      regulating the expression of KSRP, PETN, and AKT in the liver.
PG  - 16185-16194
LID - 10.1002/jcb.28898 [doi]
AB  - Insulin resistance plays a key role in the development and progression of type 2 
      diabetes mellitus (T2DM). Recent studies found that insulin resistance was 
      associated with the dysfunction of KH-type splicing regulatory protein (KSRP) 
      expression and AKT pathway, and that oxymatrine possesses an antidiabetic effect. 
      The aim of the present study was to investigate whether the protection of 
      oxymatrine against T2DM was associated with the modulation of the KSRP expression 
      and AKT pathway. Sprague-Dawley rats were fed a high-fat diet and injected with 
      streptozotocin intraperitoneally to induce T2DM, which led to an increase in 
      blood glucose levels and insulin resistance, and a decrease in insulin 
      sensitivity and glycogen synthesis concomitant with KSRP downregulation, PTEN 
      upregulation, and AKT phosphorylation deficiency. The administration of 
      oxymatrine decreased blood glucose levels and insulin resistance, increased 
      insulin sensitivity, and improved glycogen synthesis in the liver of T2DM rats, 
      through a reversal in the expression of KSRP, PTEN, and AKT. On the basis of 
      these observations, we concluded that oxymatrine can protect T2DM rats from 
      insulin resistance through the regulation of the KSRP, PETN, and AKT expression 
      in the liver.
CI  - (c) 2019 Wiley Periodicals, Inc.
FAU - Zuo, Mei-Ling
AU  - Zuo ML
AD  - Office of Good Clinical Practice, The Affiliated Changsha Hospital of Hunan 
      Normal University, Changsha, Hunan, China.
FAU - Wang, Ai-Ping
AU  - Wang AP
AUID- ORCID: 0000-0003-3392-0543
AD  - Institute of Clinical Research, Nanhua Affiliated Hospital, University of South 
      China, Hengyang, Hunan, China.
FAU - Tian, Ying
AU  - Tian Y
AD  - Institute of Clinical Research, Nanhua Affiliated Hospital, University of South 
      China, Hengyang, Hunan, China.
FAU - Mao, Li
AU  - Mao L
AD  - Department of Basic Medicine, Changsha Health Vocational College, Changsha, 
      Hunan, China.
FAU - Song, Gui-Lin
AU  - Song GL
AD  - Office of Good Clinical Practice, The Affiliated Changsha Hospital of Hunan 
      Normal University, Changsha, Hunan, China.
AD  - Institute of Emergency and Critical Care Medicine of Changsha, Changsha, China.
FAU - Yang, Zhong-Bao
AU  - Yang ZB
AUID- ORCID: 0000-0002-1334-8386
AD  - Office of Good Clinical Practice, The Affiliated Changsha Hospital of Hunan 
      Normal University, Changsha, Hunan, China.
AD  - Institute of Emergency and Critical Care Medicine of Changsha, Changsha, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190514
PL  - United States
TA  - J Cell Biochem
JT  - Journal of cellular biochemistry
JID - 8205768
RN  - 0 (Alkaloids)
RN  - 0 (Blood Glucose)
RN  - 0 (KHSRP protein, rat)
RN  - 0 (Quinolizines)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Trans-Activators)
RN  - 5W494URQ81 (Streptozocin)
RN  - 85U4C366QS (oxymatrine)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (Pten protein, rat)
SB  - IM
MH  - Alkaloids/*administration & dosage/pharmacology
MH  - Animals
MH  - Blood Glucose/drug effects
MH  - Diabetes Mellitus, Experimental/*drug therapy/metabolism
MH  - Diet, High-Fat/*adverse effects
MH  - Gene Expression Regulation/drug effects
MH  - Injections, Intraperitoneal
MH  - Insulin Resistance
MH  - Male
MH  - PTEN Phosphohydrolase/*metabolism
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - Quinolizines/*administration & dosage/pharmacology
MH  - RNA-Binding Proteins/*metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Streptozocin
MH  - Trans-Activators/*metabolism
OTO - NOTNLM
OT  - AKT
OT  - KH-type splicing regulatory protein (KSRP)
OT  - PETN
OT  - insulin resistance
OT  - oxymatrine
OT  - type 2 diabetes mellitus (T2DM)
EDAT- 2019/05/16 06:00
MHDA- 2020/08/18 06:00
CRDT- 2019/05/16 06:00
PHST- 2018/12/12 00:00 [received]
PHST- 2019/03/03 00:00 [revised]
PHST- 2019/03/15 00:00 [accepted]
PHST- 2019/05/16 06:00 [pubmed]
PHST- 2020/08/18 06:00 [medline]
PHST- 2019/05/16 06:00 [entrez]
AID - 10.1002/jcb.28898 [doi]
PST - ppublish
SO  - J Cell Biochem. 2019 Sep;120(9):16185-16194. doi: 10.1002/jcb.28898. Epub 2019 
      May 14.